-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7

Benzinga·05/05/2026 17:45:24
Listen to the news
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $7.